Physician profile
Robert S Wool
NPI 1568467132
$3,148.71
in general payments reported to CMS, 2019-2025
23 companies · $581 in 2025
The $581 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,048 · 2020: $450 · 2021: $225 · 2022: $174 · 2023: $293 · 2024: $376 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,058 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,057.90 |
| Education | $193.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $652.52 | 2019-2024 | Evenity, Prolia |
| Abbvie INC. | $599.10 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $415.20 | 2023-2025 | Veozah |
| Therapeuticsmd, INC. | $275.32 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $270.64 | 2024-2025 | Gemtesa |
| Exeltis, USA INC. | $120.57 | 2019-2025 | Slynd |
| Exact Sciences Corporation | $113.23 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $113.10 | 2019-2020 | |
| Organon LLC | $106.42 | 2022-2025 | Nexplanon, Nuvaring |
| Sage Therapeutics, LLC | $68.03 | 2024-2025 | Zurzuvae |
| Boston Scientific Corporation | $64.85 | 2019 | |
| Amag Pharmaceuticals, INC. | $58.04 | 2019 | |
| Pfizer INC. | $54.71 | 2023-2024 | |
| Roche Diagnostics Corporation | $46.74 | 2019-2020 | |
| Radius Health, INC. | $34.60 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $25.10 | 2025 | Aptima, Thinprep 2000 Processor |
| Fresenius Kabi USA, LLC | $23.76 | 2025 | |
| Agile Therapeutics, INC. | $23.10 | 2021 | |
| Supernus Pharmaceuticals, INC. | $19.66 | 2025 | Qelbree |
| Evofem Biosciences, INC. | $18.73 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.53 | 2025 | |
| Minerva Surgical, INC | $14.40 | 2022 | |
| Merck Sharp & Dohme LLC | $13.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wool listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.